Brief: NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
09/03/2026 11:20
March 9 (Reuters) - NewcelX AG NCEL.O: NEWCELX ANNOUNCES STRATEGIC COLLABORATION WITH ELEDON PHARMACEUTICALS TO ADVANCE NCEL-101 PROGRAM FOR TYPE 1 DIABETES NEWCELX AG - COLLABORATION TO INTEGRATE NCEL-101 WITH ELEDON'S TEGOPRUBART (AT-1501) Source text: ID:nPn45PTxYa Further company coverage: NCEL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewcelX AG
See all newsBrief: Newcelx Announces Pricing Of $1.4 Million Equity Financing At 20% Premium Pricing
Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
Brief: Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing